Halozyme Therapeutics, Inc. (LON:0J2O)
 64.44
 -0.85 (-1.30%)
  At close: Oct 30, 2025
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $325.72M USD in the quarter ending June 30, 2025, with 40.79% growth. This brings the company's revenue in the last twelve months to $1.18B, up 34.97% year-over-year. In the year 2024, Halozyme Therapeutics had annual revenue of $1.02B with 22.44% growth.
Revenue (ttm) 
 $1.18B
Revenue Growth 
 +34.97%
P/S Ratio 
 6.68
Revenue / Employee 
 $3.37M
Employees 
 350
Market Cap 
5.75B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 1.02B | 186.07M | 22.44% | 
| Dec 31, 2023 | 829.25M | 169.14M | 25.62% | 
| Dec 31, 2022 | 660.12M | 216.81M | 48.91% | 
| Dec 31, 2021 | 443.31M | 175.72M | 65.67% | 
| Dec 31, 2020 | 267.59M | 71.60M | 36.53% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| AstraZeneca | 41.24B | 
| GSK plc | 32.17B | 
| Haleon | 11.02B | 
| Smith & Nephew | 4.33B | 
| Hikma Pharmaceuticals | 2.35B | 
| ConvaTec Group | 1.72B | 
| Spire Healthcare Group | 1.55B | 
| Genus | 672.80M | 
Halozyme Therapeutics News
- 7 days ago - Halozyme Just Bought Its Next Decade Of Growth - Seeking Alpha
- 9 days ago - Halozyme to Report Third Quarter 2025 Financial and Operating Results - PRNewsWire
- 20 days ago - Strong And Rising: Halozyme Therapeutics Stock May Have More Upside - Forbes
- 24 days ago - Halozyme names Cortney Caudill as COO - Seeking Alpha
- 4 weeks ago - HC Wainwright & Co. Raises Price Target for Halozyme Therapeutics (HALO) | HALO Stock News - GuruFocus
- 4 weeks ago - Insider Sell: Bernadette Connaughton Sells 2,000 Shares of Halozyme Therapeutics Inc (HALO) - GuruFocus
- 4 weeks ago - Halozyme Therapeutics, Inc. (HALO) Discusses To Acquire Elektrofi Conference Call (Transcript) - Seeking Alpha
- 4 weeks ago - Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript - Seeking Alpha